MCM8 in human tumors: genome maintenance, oncogenic signaling, biomarker potential, and therapeutic vulnerabilities
Cancer Advances · 2026 · 9 · e260021
DOI: 10.53388/2026926021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Advances, 2026. Verfasst von Xu-Sheng Liu und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Minichromosome maintenance complex component 8 (MCM8) is an evolutionarily recent member of the MCM protein family that has moved from a specialized topic in DNA replication biology to a visible factor in cancer genomics, tumor progression, and DNA damage response research. Unlike the canonical MCM2–7 helicase, MCM8 functions predominantly with MCM9 and the accessory factor HROB/MCM8IP to support homologous recombination, RAD51 recruitment, DNA end resection, and the processing of stressed replication forks. Separately, MCM8 has been linked to DDX5/DHX9-associated R-loop resolution. These functions are directly relevant to cancer, where oncogene-induced replication stress, defective checkpoint control, DNA repair rewiring, and therapy resistance shape malignant evolution. Evidence from human tumors now links increased MCM8 expression, copy number gain, or pathway activation to aggressive phenotypes in prostate cancer, hepatocellular carcinoma, colorectal cancer, lung cancer, gastric cancer, glioma, bladder cancer, cholangiocarcinoma, osteosarcoma, renal cell carcinoma, esophageal carcinoma, and other malignancies. Germline studies further connect disruption of this pathway with chromosomal instability and gonadal insufficiency. Limited evidence links biallelic MCM8 variants to early-onset Lynch-like cancer, whereas emerging MCM9 and HROB studies suggest gene-specific associations with gastrointestinal polyposis or cancer that require further validation. This review synthesizes the molecular biology of MCM8, its tumor-specific evidence base, emerging oncogenic mechanisms, clinical biomarker potential, and therapeutic implications. The available literature supports MCM8 as a conditional genome maintenance factor that can become oncogenic when overexpressed or co-opted by cancer cells, whereas MCM8/MCM9 impairment can create vulnerabilities to platinum compounds, poly(ADP-ribose) polymerase inhibition, and antisense-based chemosensitization. Major limitations remain, including heavy reliance on retrospective transcriptomic analyses, incomplete separation of MCM8 from general proliferation signatures, limited prospective validation, and insufficient mechanistic mapping across tumor contexts. Future work should define tumor-selective dependencies, develop clinically reliable assays, and test whether MCM8-centered vulnerabilities can be translated into precision oncology strategies.
Zitieren
APA
Liu, X., Chen, X., & Pei, Z. (2026). MCM8 in human tumors: genome maintenance, oncogenic signaling, biomarker potential, and therapeutic vulnerabilities. Cancer Advances, 9(0), e260021. https://doi.org/10.53388/2026926021
Vancouver
Liu X, Chen X, Pei Z. MCM8 in human tumors: genome maintenance, oncogenic signaling, biomarker potential, and therapeutic vulnerabilities. Cancer Advances. 2026;9(0):e260021. doi:10.53388/2026926021
BibTeX
@article{Liu2026,
author = {Liu, Xu-Sheng and Chen, Xi and Pei, Zhi-Jun},
title = {MCM8 in human tumors: genome maintenance, oncogenic signaling, biomarker potential, and therapeutic vulnerabilities},
journal = {Cancer Advances},
year = {2026},
volume = {9},
number = {0},
pages = {e260021},
doi = {10.53388/2026926021}
}
EUVIMED